Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Autolus Therapeutics (AUTL) Net Income towards Common Stockholders (2017 - 2025)

Historic Net Income towards Common Stockholders for Autolus Therapeutics (AUTL) over the last 9 years, with Q3 2025 value amounting to -$79.1 million.

  • Autolus Therapeutics' Net Income towards Common Stockholders rose 362.51% to -$79.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$224.8 million, marking a year-over-year increase of 1680.99%. This contributed to the annual value of -$220.7 million for FY2024, which is 589.25% down from last year.
  • Latest data reveals that Autolus Therapeutics reported Net Income towards Common Stockholders of -$79.1 million as of Q3 2025, which was up 362.51% from -$47.9 million recorded in Q2 2025.
  • Over the past 5 years, Autolus Therapeutics' Net Income towards Common Stockholders peaked at -$6.8 million during Q4 2021, and registered a low of -$34.0 billion during Q3 2021.
  • Over the past 5 years, Autolus Therapeutics' median Net Income towards Common Stockholders value was -$45.6 million (recorded in 2023), while the average stood at -$1.8 billion.
  • Examining YoY changes over the last 5 years, Autolus Therapeutics' Net Income towards Common Stockholders showed a top increase of 9998.97% in 2021 and a maximum decrease of 9099205.41% in 2021.
  • Quarter analysis of 5 years shows Autolus Therapeutics' Net Income towards Common Stockholders stood at -$6.8 million in 2021, then crashed by 298.16% to -$27.0 million in 2022, then plummeted by 186.04% to -$77.2 million in 2023, then skyrocketed by 64.23% to -$27.6 million in 2024, then plummeted by 186.6% to -$79.1 million in 2025.
  • Its Net Income towards Common Stockholders was -$79.1 million in Q3 2025, compared to -$47.9 million in Q2 2025 and -$70.2 million in Q1 2025.